Three-day, In-clinic Evaluation of the BD 2nd Generation Continuous Glucose Sensor Device in Type 1 Diabetics

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Diabetes
Interventions
DEVICE

BD CGM with Outer Layer

continuous (every 2 minutes) subcutaneous glucose monitoring for 72 hours.

DEVICE

BD CGM without Outer Layer

continuous (every 2 minutes) subcutaneous glucose monitoring over 72 hours.

DEVICE

Medtronic iPro2 Professional CGM

continuous subcutaneous glucose monitoring for 72 hours

Trial Locations (1)

M4G 3E8

>LMC Endocrinology Centre, Clinical Research Unit, Toronto

Sponsors
All Listed Sponsors
lead

Becton, Dickinson and Company

INDUSTRY